<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966795</url>
  </required_header>
  <id_info>
    <org_study_id>M16-126</org_study_id>
    <secondary_id>2016-003192-22</secondary_id>
    <nct_id>NCT02966795</nct_id>
  </id_info>
  <brief_title>A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection</brief_title>
  <official_title>M16-126 A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir
      (ABT-493)/pibrentasvir (ABT-530) for an 8- or 12-week treatment duration in participants with
      chronic Hepatitis C Virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated
      cirrhosis, who are either HCV treatment-naïve or treatment experienced with interferon (IFN)
      or pegylated interferon (pegIFN) with or without ribavirin (RBV) (defined as P/R
      treatment-experienced) or sofosbuvir (SOF) plus RBV with or without pegIFN (defined as SOF
      plus RBV treatment-experienced).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 25, 2017</start_date>
  <completion_date type="Anticipated">October 4, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 14, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12) within each genotype (GT; GT5 and GT6) separately across treatment arms</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment HCV virologic failure</measure>
    <time_frame>During treatment (up to 8 or 12 weeks, treatment arm specific) and at the end of treatment with at least 6 weeks of treatment.</time_frame>
    <description>HCV virologic failure defined as:
Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurement of greater than 1 log10 IU/mL above nadir) at any time point during study drug treatment; or
Confirmed HCV RNA greater than or equal to 100 IU/mL (defined as 2 consecutive HCV RNA measurements greater than or equal to 100 IU/mL) after HCV RNA less than LLOQ during study drug treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment HCV virologic relapse</measure>
    <time_frame>At the end of treatment (8 or 12 weeks, treatment arm specific) and 12 weeks after last dose of treatment.</time_frame>
    <description>Post-treatment virologic failure (Relapse) is defined as:
- Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) between end of treatment and 12 weeks after the last dose of study drug (up to and including the SVR12 assessment time point), for subjects who completed treatment (defined as study drug duration ≥ 77 days and ≥ 105 days for subjects allocated to the 12 and 16 week durations, respectively) and had HCV RNA &lt; LLOQ at final treatment visit, excluding reinfection, as described below.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection</condition>
  <arm_group>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: HCV GT 5 or 6 participants with compensated cirrhosis treated with GLE/PIB 300 mg/120 mg QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Hepatitis C virus genotype 5 or 6 (HCV GT 5 or 6) non-cirrhotic participants treated with Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>ARM A: GLE/PIB for 8 weeks</arm_group_label>
    <arm_group_label>Arm B: GLE/PIB for 12 weeks</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening laboratory result indicating hepatitis C virus (HCV) GT5 or 6 infection.

          -  Participant has a positive anti-HCV antibody (Ab) and plasma HCV ribonucleic acid
             (RNA) greater than or equal to 1000 IU/mL at Screening Visit.

          -  Participant must be HCV treatment-naïve (i.e., has never received a single dose of any
             approved or investigational anti-HCV medication) or treatment-experienced (i.e., has
             failed prior interferon [IFN] or pegylated interferon [pegIFN] with or without
             ribavirin [RBV], or sofosbuvir [SOF] plus RBV with or without pegIFN therapy). Prior
             HCV treatment with any other approved or investigational medications is not allowed.
             Previous HCV treatment must have been completed greater than or equal to 2 months
             prior to screening.

          -  Participant must be documented as having no cirrhosis or compensated cirrhosis.

        Exclusion Criteria:

          -  Female participant who is pregnant, breastfeeding, or is considering becoming pregnant
             during the study or for approximately 30 days after the last dose of study drug.

          -  Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          -  Positive test result at screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab).

          -  HCV genotype performed during screening indicating co-infection with more than one HCV
             genotype.

          -  History of severe, life-threatening or other significant sensitivity to any excipients
             of the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research &amp; Education, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco Gener</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital Kingswood</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Lévêque</name>
      <address>
        <city>Pessac CEDEX</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <state>Ile-de-France</state>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Tropical Diseases Hos</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoa Hao Medic Co. Ltd.</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tropical Diseases Hospital</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glecaprevir</keyword>
  <keyword>pibrentasvir</keyword>
  <keyword>compensated cirrhosis</keyword>
  <keyword>non-cirrhotic</keyword>
  <keyword>interferon (IFN)</keyword>
  <keyword>pegylated interferon (pegIFN)</keyword>
  <keyword>ribavirin (RBV)</keyword>
  <keyword>sofosbuvir (SOF)</keyword>
  <keyword>Sustained Virologic Response 12 weeks post dosing (SVR12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

